1. Home
  2. MLYS vs EVLV Comparison

MLYS vs EVLV Comparison

Compare MLYS & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • EVLV
  • Stock Information
  • Founded
  • MLYS 2019
  • EVLV 2013
  • Country
  • MLYS United States
  • EVLV United States
  • Employees
  • MLYS N/A
  • EVLV N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • EVLV Computer peripheral equipment
  • Sector
  • MLYS Health Care
  • EVLV Technology
  • Exchange
  • MLYS Nasdaq
  • EVLV Nasdaq
  • Market Cap
  • MLYS 634.6M
  • EVLV 590.8M
  • IPO Year
  • MLYS 2023
  • EVLV N/A
  • Fundamental
  • Price
  • MLYS $10.26
  • EVLV $3.95
  • Analyst Decision
  • MLYS Strong Buy
  • EVLV Strong Buy
  • Analyst Count
  • MLYS 2
  • EVLV 5
  • Target Price
  • MLYS $30.00
  • EVLV $5.60
  • AVG Volume (30 Days)
  • MLYS 256.3K
  • EVLV 1.5M
  • Earning Date
  • MLYS 03-20-2025
  • EVLV 02-27-2025
  • Dividend Yield
  • MLYS N/A
  • EVLV N/A
  • EPS Growth
  • MLYS N/A
  • EVLV N/A
  • EPS
  • MLYS N/A
  • EVLV N/A
  • Revenue
  • MLYS N/A
  • EVLV $89,220,000.00
  • Revenue This Year
  • MLYS N/A
  • EVLV $28.84
  • Revenue Next Year
  • MLYS N/A
  • EVLV $30.41
  • P/E Ratio
  • MLYS N/A
  • EVLV N/A
  • Revenue Growth
  • MLYS N/A
  • EVLV 17.67
  • 52 Week Low
  • MLYS $8.58
  • EVLV $2.01
  • 52 Week High
  • MLYS $16.91
  • EVLV $5.73
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 42.15
  • EVLV 61.60
  • Support Level
  • MLYS $9.18
  • EVLV $3.20
  • Resistance Level
  • MLYS $9.97
  • EVLV $3.33
  • Average True Range (ATR)
  • MLYS 0.85
  • EVLV 0.21
  • MACD
  • MLYS -0.09
  • EVLV 0.01
  • Stochastic Oscillator
  • MLYS 34.80
  • EVLV 78.86

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and advanced sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase and primarily under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: